- ASSISTANT PROFESSOR Population Health Science and Policy
Dr. Ferket received his MD from the University of Amsterdam in the Netherlands and holds an MSc degree in Clinical Epidemiology from the Netherlands Institute for Health Sciences. In October 2013, he defended his PhD thesis “Personalized Medical Decision Making for Prevention of a First Cardiovascular Event” at the Erasmus University Medical Center in Rotterdam, the Netherlands see http://repub.eur.nl/pub/41582/. During his PhD research period, Dr. Ferket has been involved in the teaching of basic and advanced courses in medical decision making at the Erasmus University Medical Center and at the Harvard School of Public Health, Boston, MA. After a Postdoctoral Fellowship at the Department Healthcare Policy and Research at Weill Cornell Medical College, Dr. Ferket joined Mount Sinai April 2014 in the Department of Population Health Science & Policy.
ResearchDr. Ferket has authored and co-authored numerous papers on medical decision making for the management of cardiovascular disease. His publications cover topics such as cardiovascular screening, statin therapy for the prevention of cardiovascular disease, prediction of different cardiovascular disease subtypes, and the diagnostic work-up of stable angina pectoris. His current research focuses on medical decision making on cardiothoracic surgical procedures.
Ferket BS, Van Kempen BJ, Wieberdink RG, Hofman A, Steyerberg EW, Koudstaal PJ, Mosley T, Shahar E, Gottesman R, Folsom AR, Psaty B, Kizer JR, Kronmal RA, Longstreth W, Hunink MG, Ikram MA. Separate prediction of intracerebral hemorrhage and ischemic stroke. Neurology 2014; 82(20): 1804-12.
Ferket BS, Van Kempen BJ, Hunink MG, Agarwal I, Kavousi M, Franco OH, Steyerberg EW, Max W, Fleischmann KE. Predictive value of updating Framingham risk scores with novel risk markers in the U.S. general population. PLoS ONE 2014; 9(2): e88312.
Genders TS, Ferket BS, Dedic A, Galema TW, Mollet NR, de Feyter PJ, Fleischmann KE, Nieman K, Hunink MG. Coronary computed tomography versus exercise testing in patients with stable chest pain: comparative effectiveness and costs. International journal of cardiology 2013; 167(4): 1268-75.
Ferket BS, van Kempen BJ, Heeringa J, Spronk S, Fleischmann KE, Nijhuis RL, Hofman A, Steyerberg EW, Hunink MG. Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study. PLoS medicine 2012; 9(12): e1001361.
Ferket BS, Genders TS, Colkesen EB, Visser JJ, Spronk S, Steyerberg EW, Hunink MG. Systematic review of guidelines on imaging of asymptomatic coronary artery disease. Journal of the American College of Cardiology 2011; 57(15): 600.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Ferket is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 2nd FL. Room L2-70L
1425 Madison Avenue
New York, NY 10029